Results 111 to 120 of about 56,186 (320)
Risk of Cancer With Hormone Replacement Therapy: A Narrative Review
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue +3 more
wiley +1 more source
Aromatase Inhibitors for Ovulation Induction [PDF]
Normogonadotropic anovulation, including polycystic ovary syndrome (PCOS), is one of the main causes of infertility. Recent meta-analysis and randomized controlled trial suggest the use of aromatase inhibitors (ie, letrozole) as effective drug and first-line treatment to restore fertility in these patients.
openaire +3 more sources
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski +8 more
wiley +1 more source
This study compared the ecological toxicity of organic ultraviolet filters, octocrylene (OC) and ethylhexyl salicylate (EHS), on zebrafish embryos and larvae. EHS exhibited higher acute toxicity, causing increased mortality, hypoactive behavior at 50 mg/L, and disruptions in lipid homeostasis, while OC primarily affected hypoxia response and ...
Xiaoyang Lu +5 more
wiley +1 more source
Capivasertib, an AKT inhibitor, combined with fulvestrant, has demonstrated significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor (HR)-positive advanced breast cancer whose disease progressed ...
Diana Chiru, Marcus Vetter
doaj +1 more source
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy [PDF]
Yanin Chávarri-Guerra +10 more
openalex +1 more source
What anabolic–androgenic steroids reveal about the limits of current harm reduction models
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski +2 more
wiley +1 more source
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan +9 more
wiley +1 more source
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue +5 more
wiley +1 more source
Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret +5 more
wiley +1 more source

